master's thesis
Hibridna emisijska/transmisijska tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora

Matej Maršić (2016)
Sveučilište u Rijeci
Medicinski fakultet
Katedra za nuklearnu medicinu
Metadata
TitleHibridna emisijska/transmisijska tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora
AuthorMatej Maršić
Mentor(s)Svjetlana Grbac-Ivanković (thesis advisor)
Abstract
Ovaj rad obuhvaća analizu 122 pacijenta sa 163 pretrage 99mTc-Tektrotydom® SPECT/CT tehnologijom u periodu od 12.10.2012. do 17.12.2015. Svi podaci uzimani su retrospektivno. Važniji rezultati općih podataka pokazuju: stalan porast broja pacijenata; pacijente na pretrazi čini 55% žena i 45% muškaraca; velik broj pacijenata na pretrazi nakon navršene 50. godine (91% ima 50 godina ili više); prosječna dob pacijenta na pretrazi 62,3 godine. Dobiveni su i podaci koji su u užem smislu medicinski: 60% pacijenata na pretragu je uputio onkolog; 21 pacijent je imao potvrđenu patohistološku dijagnozu NET-a, uz napomenu da podaci nisu bili dostupni za sve pacijente. PET/CT nalaz imalo je 21% pacijenata, uz napomenu da su podaci analizirani samo ako je pacijent donio fotokopirani PET/CT nalaz, a nadležni liječnik ga je spremio u karton. Prosječni broj dana od PET/CT do SPECT/CT snimanja iznosio je 120 dana, a medijan 65,5 dana. PET/CT i SPECT/CT akumulacije u lezijama se poklapaju u 43% kod solitarnih i u 48% kod multiplih lezija. PET tehnologija je zabilježila veći broj akumulirajućih lezija nego SPECT. U skupini pacijenata s više lezija 31% lezija je vidljivo PET-om, a ne SPECT-om. Osjetljivost SPECT-a s 99mTc-Tektrotydom® u ovom radu iznosi 71%. Postotak pacijenata s proširenom bolešću (prema SPECT snimanju) iznosio je 30%, a od tog postotka 36% pacijenata je imalo PET/CT nalaz. Dvije najčešće pretrage preporučene nakon snimanja su MR i/ili CT te PET/CT. Nalaz kromogranina A u krvi imalo je 41% pacijenata. Od 39 pacijenata s povišenim kromograninom A 38% imalo je patološku akumulaciju u SPECT/CT nalazu.
Keywordsneuroendocrine tumor (NET) single photon emission computerised tomography and computed tomography (SPECT/CT) positron emission tomography and computed tomography (PET/CT) sensitivity of SPECT chromogranin A
Committee MembersMarija Petković (committee chairperson)
Tatjana Bogović Crnčić (committee member)
Ingrid Belac-Lovasić (committee member)
GranterSveučilište u Rijeci
Medicinski fakultet
Lower level organizational unitsKatedra za nuklearnu medicinu
PlaceRijeka
StateCroatia
Scientific field, discipline, subdisciplineBIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Nuclear Medicine
Study programme typeuniversity
Study levelintegrated undergraduate and graduate
Study programmeMedicine
Academic title abbreviationdr. med.
Genremaster's thesis
Language Croatian
Defense date2016-07-15
Parallel abstract (English)
This paper was based on 122 patients with 163 imagings with 99mTc-Tektrotyd® SPECT/CT from 12/10/2012 to 17/12/2015. All the data were collected retrospectively. General data show: constant increasing number of patients; patients on imaging were 55% women and 45% men; majority of patients older than 50 (91% of patients are 50 or older); average age of patients on imaging is 62,3. There are also data that are medical in the strict sense. Oncologists sent 60% of the patients. Histopathological diagnosis of NET was found in 21 patient, noting that the data were not available for all the patients. In 21% of patients PET/CT was performed, noting that this information was recorded only if the patient brought a copy of a PET/CT finding to the doctor, and it was archived. Elapsed time between PET/CT and SPECT/CT was 120 days, and the median was 65,5 days. Lesions with accumulation were concordant in PET/CT and SPECT/CT imaging comprised 43% of the cases with solitary lesions, and 48% of the multiple lesions. By PET/CT imaging more positive lesions were registered than by SPECT/CT. In the group of patients with multiple lesions there were 31% of accumulating lesions that were visible in PET/CT, but not in SPECT/CT. Sensitivity of SPECT with s 99mTc-Tektrotyd® was 71%. According to the accumulations in SPECT/CT there were 30% of patients with advanced disease, of which 36% had PET/CT. Most frequent tests recommended were MR and/or CT and PET/CT. Results show that 41% of patients had chromogranin A levels determined. There were 39 patients with elevated chromogranin A levels, of which 38% had a pathologic accumulation visible on SPECT/CT.
Parallel keywords (Croatian)neuroendokrini tumor (NET) jednofotonska emisijska računalna tomografija s računalnom tomografijom (SPECT/CT) pozitronska emisijska tomografija s računalnom tomografijom (PET/CT) osjetljivost SPECT-a kromogranin A
Resource typetext
Access conditionAccess restricted to students and staff of home institution
Terms of usehttp://rightsstatements.org/vocab/InC/1.0/
URN:NBNhttps://urn.nsk.hr/urn:nbn:hr:184:040661
CommitterBosa Licul